New York-based Weill Cornell Medical College and NewYork-Presbyterian Hospital announced this week that they are teaming up to create a new medicine research hub that will focus on delivering precision medicine and individualized treatments based on the genetic profiles of patients.
The new entity--dubbed the Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center--will use "state-of-the-art technology" to enable genomics sequencing, biobanking and bioinformatics, according to Mark Rubin, a professor of pathology and laboratory medicine at Weill Cornell. Rubin has been tapped to lead the institute's efforts.
"This institute will revolutionize the way we treat disease, linking cutting-edge research and next-generation sequencing in the laboratory to the patient's bedside," Rubin said in the announcement. "We will use advanced technology and the collective wealth of knowledge from our clinicians, basic scientists, pathologists, molecular biologists and computational biologists to pinpoint the molecular underpinnings of disease--information that will spur the discovery of novel treatments and therapies."
The Mayo Clinic, earlier this month, announced a strategic partnership with diagnostics company Silicon Valley Biosystems to advance personalized medicine through genomics. That arrangement is similar to one also recently planned by Children's Hospital Boston and Life Technologies.
What's more, last fall, UPMC announced that it was investing $100 million to develop a robust data warehouse that will use analytics for predictive modeling.
For more information:
- read the Weill Cornell announcement